Kamada Stock Sees Q3 Earnings Forecast Lowered at Sidoti

Kamada Ltd. (NASDAQ:KMDA) – Equities researchers at Sidoti decreased their Q3 2028 earnings per share (EPS) estimates for Kamada in a research note issued to investors on Friday, September 25th. Sidoti analyst J. Sidoti now forecasts that the biotechnology company will earn $0.13 per share for the quarter, down from their previous forecast of $0.15. The consensus estimate for Kamada’s current full-year earnings is $0.48 per share.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.05. The company had revenue of $54.92 million for the quarter, compared to analysts’ expectations of $50.84 million. Kamada had a return on equity of 8.37% and a net margin of 11.60%.

Several other equities research analysts have also recently weighed in on the company. William Blair set a $15.00 target price on Kamada in a research note on Tuesday, July 21st. Benchmark restated a “buy” rating on shares of Kamada in a research report on Tuesday, July 21st. Weiss Ratings restated a “buy (b-)” rating on shares of Kamada in a report on Tuesday, September 22nd. UBS Group reiterated a “buy” rating and set a $15.00 price target on shares of Kamada in a research note on Friday, September 18th. Finally, Wall Street Zen raised shares of Kamada from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $13.50.

Kamada Stock Performance

NASDAQ:KMDA opened at $8.20 on Friday. Kamada has a 1 year low of $6.50 and a 1 year high of $9.35. The stock has a market cap of $471.58 million, a P/E ratio of 21.58, a P/E/G ratio of 0.71 and a beta of 0.89. The stock has a 50-day simple moving average of $7.98 and a 200-day simple moving average of $7.88.

Kamada Cuts Dividend

The firm also recently disclosed an annual dividend, which was paid on Thursday, September 17th. Shareholders of record on Thursday, August 27th were given a dividend of $0.17 per share. This represents a yield of 206.0%. The ex-dividend date of this dividend was Thursday, August 27th. This is a decrease from Kamada’s previous annual dividend of $0.25. Kamada’s payout ratio is 34.21%.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Kamada stock. Aristides Capital LLC grew its holdings in Kamada Ltd. (NASDAQ:KMDA) by 4.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 33,015 shares of the biotechnology company’s stock after buying an additional 1,430 shares during the period. Aristides Capital LLC owned 0.06% of Kamada worth $233,000 at the end of the most recent reporting period. 20.38% of the stock is owned by institutional investors.

Kamada Company Profile

Kamada Ltd. is an Israel-based biopharmaceutical company focused on the development, manufacture and commercialization of plasma-derived and specialty pharmaceutical products. The company’s portfolio is aimed primarily at treating rare diseases and other conditions requiring replacement or immune-modulating therapies.

Kamada’s principal product is GLASSIA, an intravenous alpha-1 proteinase inhibitor used as augmentation therapy in adults with alpha-1 antitrypsin deficiency, a rare genetic disorder that can cause progressive lung disease.